Center Without Walls for Imaging Proteinopathies With PET

The goal of the CW2IP2 is to use state-of-the-art in silico methods to identify “hits” that can function as lead compounds for PET radiotracer development for imaging alpha synuclein for the synucleinopathies (PD, MSA) and 4R tau for the 4R tauopathies (CBD, PSP). There are two steps in the overall process:

Step 1: In silico identification of lead compounds and SAR StudiesStep 2: Preliminary imaging studies in nonhuman primate